Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Cytosorbents Corp Director's Dealing 2021

Apr 15, 2021

34501_dirs_2021-04-14_66e17943-0114-4502-b7a8-bf94c2bcd6f9.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cytosorbents Corp (CTSO)
CIK: 0001175151
Period of Report: 2021-04-12

Reporting Person: Deliargyris Efthymios (Chief Medical Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-04-12 Common Stock A 40000 $8.99 Acquired 183000 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-04-12 Stock Option (right to buy) $8.99 A 63250 Acquired 2031-04-12 Common Stock (63250) Direct

Footnotes

F1: These shares represent restricted stock units ("RSUs") which shall vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting.

F2: Includes: (i) 120,000 RSUs granted on April 9, 2020 that will be settled into common stock, par value $0.001 per share (the "Common Stock") upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Company") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan;

F3: (ii) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into Common Stock upon vesting: (a) 40,000 RSUs granted on April 12, 2021 and unvested on the date hereof and (b) 20,000 RSUs granted on April 9, 2020 and unvested on the date hereof; and (iii) 3,000 shares of Common Stock owned by the reporting person.

F4: The stock options were granted pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan. The shares underlying the stock options vest as to one-quarter of the award on each of the date of grant, the first anniversary of the date of grant, the second anniversary of the date of grant and the third anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.